Skip to content
Home » Projects


Blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare blood cancer originating from precursor dendritic cells. This form of rare cancer has often gone underdiagnosed due to misclassification and lack of knowledge. To address this, CPE aims to increase awareness amongst society to promote positive outcomes. Read More


Why it matters The aim of QUALITOP is to serve as a dedicated digital platform for assembling data on the health and quality of… Read More


CPE is a consortium member of the EU-funded-project: GLIOMATCH which seeks to revolutionise treatment outcomes for Paediatric High-grade Glioma (pHGG) and Glioblastoma Multiforme (GBM) patients through advanced immunology-based stratification and therapy matching. Read More

myC – my Cancer my Concern

Launched in 2022, myC (my Cancer my Concern) aims to raise awareness of the benefits and values of genomic testing in cancer, educate patients and stakeholders, and improve accessibility to genomic testing across Europe. Read More


CPE is a consortium member of the EU-funded project: PREVENT. It aims to tackle childhood obesity to mitigate cancer risks in adulthood. As a crucial partner, CPE contributes expertise to drive outreach, identify barriers, and develop effective strategies. Read More

INTERCEPTOR – INTercEption of oRal CancEr develoPmenT

CPE is a collaborating partner of the INTERCEPTOR project together with IARC, OECI, and EORTC. This is a project funded within the COST ACTION programme with 125 participants. It aims to develop personalised strategies for oral potentially malignant disorders. We lead communication efforts to ensure these innovations benefit all EU citizens. Read More